Tag: Lc faod

Triheptanoin, marketed as Dojolvi, received FDA approval in 2020 as a groundbreaking treatment for patients with long-chain fatty acid oxidation disorders (LC-FAOD). The primary function of triheptanoin is to serve as an alternative energy substrate, providing a crucial source of calories and fatty acids for individuals unable to metabolize long-chain fats effectively.

According to the National Institutes of Health, long-chain fatty acid oxidation disorders (LC-FAODs) are rare, inherited conditions affecting approximately 1 in 9,300 individuals in some populations. A breakdown in metabolism due to these disorders is the primary cause of severe side effects associated with long chain fatty acids.

According to product information from its manufacturer, Nutricia, Monogen is specifically formulated as a low-fat powdered feed enriched with medium-chain triglycerides (MCTs). This specialized formula is designed for dietary management in patients requiring a reduced long-chain fat intake, addressing conditions related to fat malabsorption and metabolic disorders under medical supervision.

For individuals with specific genetic conditions like long-chain fatty acid oxidation disorders (LC-FAOD), strict dietary modifications are critical for health management. These patients require specialized knowledge on **how to avoid long chain fatty acids** to prevent serious health complications, a distinctly different approach than general healthy eating advice.